Streetbeat News

Stock Prices

CTXR

Trading halt status for CTXR was updated at 7:25:00 AM ET. The news and resumption times have been provided.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:25 am

PEP

TSLA

Tesla is delivering 50 more Semi trucks to PepsiCo, expanding PepsiCo's fleet to 86 Semis. Tesla is also building a high-volume Semi factory at Giga Nevada, with production for external customers starting in 2026.

Portfolio Pulse from Anan Ashraf

May 21, 2024 | 11:24 am

Kanzhun Ltd reported strong Q1 2024 results with revenues of $236.0M, up 33.4% YoY, and calculated cash billings of $284.0M, up 24.3% YoY. Average monthly active users increased by 17.4% YoY to 46.6M, and total paid enterprise customers grew by 42.5% YoY to 5.7M.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:23 am

LOW

Lowe's Companies Inc (NYSE:LOW) reported better-than-expected Q1 FY24 earnings, with EPS of $3.06 beating estimates. Despite a 4.4% revenue decline to $21.364 billion, the company saw positive comparable sales in Pro and online segments. Gross profit fell 5.8%, and operating income dropped 19.3%. Lowe's affirmed its FY24 outlook, expecting revenue of $84-$85 billion and EPS of $12.00-$12.30. Shares are trading higher by 2.54% in premarket.

Portfolio Pulse from Shivani Kumaresan

May 21, 2024 | 11:22 am

CYD

The first batch of green energy buses equipped with Yuchai Xingshunda hydrogen fuel cells has been launched. This development is significant for the green energy sector and highlights the advancements in hydrogen fuel cell technology.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:17 am

CTXR

Citius Pharmaceuticals announced that its Phase 3 trial of Mino-Lok met its primary endpoint, showing a statistically significant improvement in the time to failure event compared to the control arm patients receiving clinician-directed anti-infective lock solution.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:16 am

AZN

AstraZeneca (NASDAQ: AZN) has announced an ambitious plan to increase its total revenue to $80 billion by 2030, up from $45.8 billion in 2023. The growth will be driven by expanding its oncology, biopharmaceuticals, and rare disease portfolios, and introducing 20 new medicines by the end of the decade. The company will also invest in transformative technologies and platforms to sustain growth beyond 2030. AstraZeneca aims to achieve a mid-30s percentage core operating margin by 2026 and maintain it post-2026. Analysts have mixed views on the revenue target, with some seeing a 20% upside to the 2030 consensus.

Portfolio Pulse from Vandana Singh

May 21, 2024 | 11:16 am

AZO

IWM

LOW

NVDA

PANW

QQQ

SPY

TOL

URBN

VSAT

Wall Street is expected to open mostly flat as traders await Nvidia's earnings and several Fed speeches. Bitcoin surged above $71K on Ethereum ETF approval speculation. Key stocks in focus include Nvidia, Palo Alto Networks, Zoom Video Communications, Lowe's, AutoZone, Macy's, Toll Brothers, Viasat, and Urban Outfitters.

Portfolio Pulse from Shanthi Rexaline

May 21, 2024 | 11:14 am

YMM

Full Truck Alliance shares are trading higher following a Q1 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:11 am

GLUE

Monte Rosa Therapeutics will present preclinical data at Digestive Disease Week 2024, showing that MRT-6160-mediated degradation of VAV1 inhibited disease progression in a T-cell transfer murine model of colitis. VAV1 is a key signaling protein with potential to treat multiple autoimmune and inflammatory diseases.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 11:09 am